Each autumn, the act of rolling up a sleeve for a flu shot has carried the quiet weight of collective protection — a ritual so familiar it can obscure the science still evolving beneath it. In August 2026, the FDA approved mFLUSIVA, the first mRNA-based influenza vaccine in the United States, extending a technology forged in the crucible of a pandemic into the older, more ordinary battle against seasonal flu. For adults 50 and older, this approval does not replace the ritual — it deepens it, offering a 27 percent lower relative risk of flu illness and, perhaps more significantly, a platform ca